S100A4 expression and prognosis of gastric cancer: a meta-analysis

Y. Wang*, L.-B. Zhou* and X.-H. Li

1Department of General Surgery, Second Affiliated Hospital of Anhui Medical University, Hefei, China
2Department of Digestive Medicine, Shanghai Eighth People’s Hospital, Shanghai, China

*These authors contributed equally to this study.
Corresponding author: X.-H. Li
E-mail: lixinghua212@yeah.net

Received October 9, 2013
Accepted July 26, 2014
Published December 12, 2014
DOI http://dx.doi.org/10.4238/2014.December.12.1

ABSTRACT. The prognostic role of S100A4 in gastric cancer is still under debate. The present meta-analysis aimed to evaluate the relationship between S100A4 levels and the prognosis of gastric cancer. We performed a meta-analysis of published studies assessing the relationship between S100A4 and gastric cancer prognosis. We used the Revman 5.0 software to perform literature retrieval, article selection, data collection, and statistical analysis. A fixed-effect model was used to pool the hazard ratio (HR) and 95% confidence intervals (95%CI). A total of 7 eligible studies that included 1257 gastric cancer patients were analyzed. We did not find a prognostic value for S100A4 in gastric cancer (HR = 1.48, 95%CI = 0.77 to 2.82, P = 0.24). In conclusion, the present study indicated that S100A4 expression level is not a prognostic factor for gastric cancer.

Key words: S100A4; Prognosis; Gastric cancer; Meta-analysis
INTRODUCTION

Gastric cancer is one of the most common causes of cancer-related death in recent years (El-Rifai and Powell, 2002). Worldwide, approximately 876,000 people are diagnosed with this disease every year and approximately 649,000 succumb (Durrani et al., 2009). In China, there are approximately 160,000 deaths from gastric cancer annually (Chen et al., 2004). A number of studies have reported the relationship between S100A4 expression and the prognosis of gastric cancer (Yonemura et al., 2000; Yu et al., 2006; Huang et al., 2008; Wang et al., 2010; Feng et al., 2011; Stein et al., 2011; Zhao et al., 2013; Li et al., 2013) However, the association of S100A4 with gastric prognosis remains unclear.

The S100 protein family was first isolated from bovine brain by Moore (1965). Subsequent studies identified 16 members of this family, based on amino acid sequence homology and similar structural properties (Schafer and Heizmann, 1996). S100A4 is highly expressed in many cancers (Kikuchi et al., 2006; Ai et al., 2008; Kwak et al., 2010) and its presence predicts a poor outcome, such as in pancreatic cancer, (Ai et al. 2008), colorectal cancer (Kwak et al., 2010), ovarian carcinoma (Kikuchi et al., 2006), bladder carcinoma (Yao et al. 2007), esophageal carcinoma (Ji et al., 2004), and gastric carcinoma (Yonemura et al., 2000; Yu et al., 2006; Huang et al., 2008; Feng et al., 2011; Wang et al., 2010; Stein et al., 2011; Zhao et al., 2013; Li et al., 2013). However, the prognostic value of S100A4 in patients with gastric cancer is still controversial. This study was a retrospective analysis of published studies to evaluate the prognostic value of S100A4 level before treatment in patients with gastric cancer.

MATERIAL AND METHODS

Publication search

We searched the PubMed, Medline, Embase, AACR (American Association for Cancer Research), Chinese Biomedical Literature Database, China National Knowledge Infrastructure (CNKI), and Wanfang databases using the search terms “S100A4” and “gastric cancer” or “gastric carcinoma” and “prognosis” updated until July 2013. The online search was accompanied by checking reference lists from the articles and reviews identified for potentially eligible original reports.

Inclusion criteria

The inclusion criteria were as follows: 1) clinical research on direct comparison of S100A4 levels in gastric cancer before and after treatment, without any restriction on language or publication year; 2) research subjects were gastric cancer patients without any restriction on age or race; 3) outcome indicators: overall survival.

Exclusion criteria

The major exclusion criteria were as follows: 1) duplicate data; 2) case reports, series, abstract, comment, review, and editorial; 3) insufficient data.
Literature quality assessment and data extraction

We collected the information as follows: author, year of publication, country of origin, ethnicity, number of cases, and S100A4 detection method. In a few studies, part of the data had already been reported elsewhere, therefore, only the novel data was included.

Data analysis

Meta-analysis was performed by using the RevMan 5.0 software provided by the Cochrane Collaboration. We directly used the q-test and the I² test to examine the heterogeneity between each study. We used the hazard ratio (HR) value to evaluate the relationship between the S100A4 level and overall survival in gastric cancer. To test for publication bias, we used the RevMan 5.0 statistical software to make the funnel plot. P < 0.05 was considered as indicating a significant difference.

RESULTS

Literature screening

A total of 104 articles were initially identified, 97 articles were excluded because of duplicate publication and non-clinical research study. A total of 7 articles were included, of which all were clinical studies, with four belonging to the Chinese literature and three to English literature (Table 1). The 7 studies including 1257 patients were included in this research.

Table 1. Characteristics of the studies included.

<table>
<thead>
<tr>
<th>First Author</th>
<th>Publication year</th>
<th>Country</th>
<th>HR</th>
<th>95%CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Li</td>
<td>2013</td>
<td>China</td>
<td>10.129</td>
<td>4.56-21.43</td>
</tr>
<tr>
<td>Feng</td>
<td>2011</td>
<td>China</td>
<td>3.233</td>
<td>1.04-5.42</td>
</tr>
<tr>
<td>Stein</td>
<td>2011</td>
<td>Germany</td>
<td>2.76</td>
<td>1.03-4.98</td>
</tr>
<tr>
<td>Huang</td>
<td>2008</td>
<td>China</td>
<td>2.126</td>
<td>1.0-4.099</td>
</tr>
<tr>
<td>Yu</td>
<td>2006</td>
<td>China</td>
<td>3.12</td>
<td>2.11-6.33</td>
</tr>
<tr>
<td>Wang</td>
<td>2010</td>
<td>China</td>
<td>2.19</td>
<td>1.33-3.55</td>
</tr>
<tr>
<td>Yonemura</td>
<td>2000</td>
<td>Switzerland</td>
<td>2.43</td>
<td>1.32-4.35</td>
</tr>
</tbody>
</table>

S100A4 level and prognosis for gastric cancer

In 3 of these 7 studies, we extracted the HR values and their 95%CI directly and used them for the evaluation of the association of S100A4 levels with the prognosis of gastric cancer. In the other four studies, the HR values and their 95%CI could be calculated according to the data. There was better homogeneity between each study (P = 1.00, I² = 0%). We did not find a prognostic value for S100A4 in gastric cancer. (HR = 1.48, 95%CI = 0.77 to 2.82, P = 0.24; Figure 1).

Publication bias analysis

We analyzed publication bias by use of the Revman 5.0 software. The funnel plot (Figure 2) showed the points evenly distributed, and most of the points were within the 95%CI. It indicated that there was no publication bias, and thus, the results of the study were credible.
DISCUSSION

In the present study, we found that S100A4 was not associated with the prognosis of gastric cancer by a meta-analysis.
The S100A4 protein is one of 24 members of the S100 family. The S100 proteins regulate the interaction between Ca\(^{2+}\) and target proteins. S100A4 is involved in the regulation of a wide range of intracellular and extracellular biological effects, including cell motility, angiogenesis, cell survival, differentiation, contractility and invasion (Stein et al., 2006). Studies have indicated that S100A4 is associated with tumor invasion and metastasis, and that it may be a potential prognostic marker. Kwak et al. (2010) detected immunoreactivity for S100A4 in 45 (35.4\%) of 127 colorectal cancers and found that S100A4 protein expression was associated with tumor recurrence and poor overall survival in patients with colorectal cancer. Kikuchi et al. (2006) demonstrated that nuclear expression of S100A4 was involved in the aggressive behavior of ovarian carcinoma and that S100A4 is an autocrine/paracrine factor that plays an important role in the aggressiveness of ovarian carcinoma cells. However, the association of S100A4 with gastric cancer remains controversial. In the present study, we performed a meta-analysis including 1257 patients with gastric cancer and did not find any association of S100A4 concentration with poor prognosis of gastric cancer. The seven studies included in this meta-analysis had clear diagnostic, inclusion and exclusion criteria. The patients were grouped according to S100A4 levels, and the overall survival was the main outcome. The HR value was a statistical indicator to assess the impact of different levels of S100A4 on overall survival of patients with gastric cancer. Also, the present study included not only the English literature, but also the Chinese literature for which the full texts could be provided and the summaries of the unpublished studies were excluded. However, this method might have caused selection bias.

In summary, this meta-analysis of 7 studies showed that the S100A4 level is not of prognostic significance in patients with gastric cancer.

REFERENCES


---

S100A4 and gastric cancer